Know Cancer

forgot password

Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies

Open (Enrolling)
Wilms' Tumor, Aniridia

Thank you

Trial Information

Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies

If you choose to take part in this study, blood (about 10 teaspoons) will be drawn for
genetic testing. The blood may be drawn more than 1 time, depending on how much blood is
drawn at the first visit, and if you are available for more blood draws. If this is the
case, your doctor will discuss any extra blood draws with you.

For small children (less than 5 years old), about 2 teaspoons will be drawn. Children who
are 5 years old or older will not have more than 3 teaspoons drawn.

You will complete a questionnaire about your medical history and family medical history.
The questionnaire should take about 1 hour to complete. The study staff will also review
your medical records.

You will be asked to allow the study staff to collect any of your tissue (whether healthy or
cancerous) that is leftover from surgeries performed as part of your standard care. This
may be from any past or future surgeries or any tissue being stored at MD Anderson or
elsewhere. No new surgeries or biopsies will be performed for this study.

Before your information, tissue samples, and/or bodily fluids can be used for research, the
people doing the research must get specific approval from the Institutional Review Board
(IRB) of MD Anderson. The IRB is a committee made up of doctors, researchers, and members
of the community. The IRB is responsible for protecting the participants involved in
research studies and making sure all research is done in a safe and ethical manner. All
research done at MD Anderson, including research involving your information, tissue samples,
and/or bodily fluids, must first be approved by the IRB.

You may be contacted either by phone or mail 1 time a year, so that the study staff can
update your medical history and information. If contacted by phone, this call should last
about 30 minutes.

Up to 1500 patients and family members will take part in this study. All will be enrolled
at MD Anderson.

Inclusion Criteria:

1. Patients with familial and sporadic Wilm's tumor, genitourinary anomalies,
Beckwith-Wiedemann hemihypertrophy and/or aniridia, and family members of patients.

Exclusion Criteria:

1. Patients who do not meet inclusion eligibility criteria are excluded.

Type of Study:


Study Design:

Observational Model: Family-Based, Time Perspective: Prospective

Outcome Measure:

Genetic Events Involved in Development of Wilms' tumor, Genitourinary Anomalies, Hemihypertrophy and Beckwith-Wiedemann, and/or Aniridia

Outcome Description:

Characterize genetic events by a combined molecular biology/epidemiologic approach

Outcome Time Frame:

32 Years (Descriptive data collected using questionnaires)

Safety Issue:


Principal Investigator

Louise C. Strong, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

December 1980

Completion Date:

Related Keywords:

  • Wilms' Tumor
  • Aniridia
  • Wilms' Tumor
  • Genitourinary Anomalies
  • Beckwith-Wiedemann Hemihypertrophy
  • Aniridia
  • Questionnaire
  • Aniridia
  • Wilms Tumor
  • Urogenital Abnormalities



UT MD Anderson Cancer Center Houston, Texas  77030